journal
MENU ▼
Read by QxMD icon Read
search

Alimentary Pharmacology & Therapeutics

journal
https://www.readbyqxmd.com/read/28083929/the-risk-predictive-values-of-uk-pbc-and-globe-scoring-system-in-chinese-patients-with-primary-biliary-cholangitis-the-additional-effect-of-anti-gp210
#1
F Yang, Y Yang, Q Wang, Z Wang, Q Miao, X Xiao, Y Wei, Z Bian, L Sheng, X Chen, D Qiu, J Fang, R Tang, M E Gershwin, X Ma
BACKGROUND: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. AIM: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems...
January 13, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28078798/systematic-review-with-meta-analysis-rifaximin-is-effective-and-safe-for-the-treatment-of-small-intestine-bacterial-overgrowth
#2
REVIEW
L Gatta, C Scarpignato
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome, characterised by an increased number and/or abnormal type of bacteria in the small bowel. Over the past decades, rifaximin has gained popularity for this indication despite its use is not evidence based. AIM: To perform a systematic review and meta-analysis to summarise evidence about the efficacy and safety of rifaximin to eradicate SIBO in adult patients. METHODS: MEDLINE, EMBASE, CCRCT, Scopus and Web of Science were searched from inception to March 16, 2015 for RCTs and observational studies...
January 12, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28078750/metabolic-adaptation-of-colonic-microbiota-to-galactooligosaccharides-a-proof-of-concept-study
#3
M Mego, C Manichanh, A Accarino, D Campos, M Pozuelo, E Varela, J Vulevic, G Tzortzis, G Gibson, F Guarner, F Azpiroz
BACKGROUND: Prebiotics have been shown to reduce abdominal symptoms in patients with functional gut disorders, despite that they are fermented by colonic bacteria and may induce gas-related symptoms. AIM: To investigate changes in the metabolic activity of gut microbiota induced by a recognised prebiotic. METHODS: Healthy subjects (n = 20) were given a prebiotic (2.8 g/day HOST-G904, HOST Therabiomics, Jersey, Channel Islands) for 3 weeks...
January 12, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28078736/investigation-of-underlying-comorbidities-as-risk-factors-for-symptomatic-human-hepatitis-e-virus-infection
#4
S Zhang, C Chen, J Peng, X Li, D Zhang, J Yan, Y Zhang, C Lu, J Xun, W Li, Y Ling, Y Huang, L Chen
BACKGROUND: Symptomatic Hepatitis E virus (HEV) infection occurs in few infected subjects, and the risk factors are not completely known. AIMS: To explore the risk factors for adverse clinical outcomes in acute HEV infections. METHODS: A large retrospective study was conducted. The baseline characteristics, clinical outcomes, and laboratory data of 512 acute HEV infection cases were analysed using logistic regression models. RESULTS: All patients exhibited autochthonous sporadic HEV infections, and most were elderly...
January 12, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28078723/real-world-use-effectiveness-and-safety-of-anti-viral-treatment-in-chronic-hepatitis-c-genotype-3-infection
#5
M Cornberg, J Petersen, A Schober, S Mauss, K H W Böker, R Link, R Günther, Y Serfert, H Pfeiffer-Vornkahl, M P Manns, C Sarrazin, D Hüppe, T Berg, C Niederau
BACKGROUND: Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data. AIM: To validate the use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection under real-word conditions. METHODS: The German Hepatitis C-Registry is a large national non-interventional real-world study for patients with chronic hepatitis C...
January 12, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28074618/review-article-dose-optimisation-of-infliximab-for-acute-severe-ulcerative-colitis
#6
REVIEW
P Hindryckx, G Novak, N Vande Casteele, D Laukens, C Parker, L M Shackelton, N Narula, R Khanna, P Dulai, B G Levesque, W J Sandborn, G D'Haens, B G Feagan, V Jairath
BACKGROUND: Although optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen. AIM: To assess the strength of the current evidence for the relationship between infliximab pharmacokinetics, dosing strategies and disease behaviour in patients with acute severe UC...
January 11, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28074540/complications-of-percutaneous-liver-biopsy-with-klatskin-needles-a-36-year-single-centre-experience
#7
V Takyar, O Etzion, T Heller, D E Kleiner, Y Rotman, M G Ghany, N Fryzek, V H Williams, E Rivera, S Auh, T J Liang, J H Hoofnagle, C Koh
BACKGROUND: Liver biopsy is the gold standard in evaluating liver diseases but is susceptible to complications. Safety data on aspiration needle biopsies remain limited. AIM: To evaluate the safety of percutaneous liver biopsy performed with Klatskin needle. METHODS: Clinical and biochemical data were retrospectively retrieved from sequential subjects who underwent liver biopsy with Klatskin needle from 1978 to 2015. Subjects with complications underwent thorough chart reviews for hospital course...
January 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28074487/higher-25-hydroxyvitamin-d-levels-are-associated-with-greater-odds-of-remission-with-anti-tumour-necrosis-factor-%C3%AE-medications-among-patients-with-inflammatory-bowel-diseases
#8
R W Winter, E Collins, B Cao, M Carrellas, A M Crowell, J R Korzenik
BACKGROUND: Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD. AIM: To evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication. METHODS: A total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion...
January 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28070899/sofosbuvir-based-treatment-regimens-real-life-results-of-14-409-chronic-hcv-genotype-4-patients-in-egypt
#9
A Elsharkawy, R Fouad, W El Akel, M El Raziky, M Hassany, G Shiha, M Said, I Motawea, T El Demerdash, S Seif, A Gaballah, Y El Shazly, M A M Makhlouf, I Waked, A O Abdelaziz, A Yosry, M El Serafy, M Thursz, W Doss, G Esmat
BACKGROUND: Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment Programme introduced sofosbuvir-based therapy in October 2014. AIM: To assess the clinical effectiveness and predictors of response to SOF-based treatment regimens, either dual therapy, with SOF/ribavirin (RBV) for 6 months or triple therapy with SOF/peg-IFN-alfa-2a/RBV for 3 months, in a cohort of patients treated in National Treatment Programme affiliated centres in Egypt...
January 9, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28052442/serum-alkylresorcinols-as-biomarkers-of-dietary-gluten-exposure-in-coeliac-disease
#10
R S Choung, J A Murray, E V Marietta, C T Van Dyke, A B Ross
BACKGROUND: Therapy for coeliac disease (CD) mainly relies on following a gluten-free diet (GFD); however, a serum marker for gluten intake has yet to be established. AIMS: To evaluate the utility of alkylresorcinol concentrations for detecting gluten intake in studies of human and mouse. METHODS: Alkylresorcinol concentrations were compared among treated patients with coeliac disease (n = 34), untreated coeliac disease patients (n = 36) and controls (n = 33)...
January 4, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28052382/systematic-review-with-meta-analysis-vasoactive-drugs-for-the-treatment-of-hepatorenal-syndrome-type-1
#11
REVIEW
F J Gifford, J R Morling, J A Fallowfield
BACKGROUND: Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant unmet need for a widely approved, safe and effective pharmacological treatment. AIM: To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in the light of recently published randomised controlled trials (RCTs)...
January 4, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28028821/sarcopenia-is-associated-with-severe-liver-fibrosis-in-patients-with-non-alcoholic-fatty-liver-disease
#12
S Petta, S Ciminnisi, V Di Marco, D Cabibi, C Cammà, A Licata, G Marchesini, A Craxì
BACKGROUND: Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD). AIM: To test the prevalence of sarcopenia and its relation with the severity of fibrosis (main outcome) and the entire spectrum of liver histology in patients with NAFLD. METHODS: We considered 225 consecutive patients with histological diagnosis of NAFLD (Kleiner score)...
December 27, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28025840/long-term-outcome-of-infliximab-treatment-in-chronic-active-ulcerative-colitis-a-swedish-multicentre-study-of-250-patients
#13
L Angelison, S Almer, A Eriksson, P Karling, U Fagerberg, J Halfvarson, M Thörn, J Björk, U Hindorf, R Löfberg, A Bajor, H Hjortswang, P Hammarlund, O Grip, J Torp, J Marsal, E Hertervig
BACKGROUND: Real-life long-term data on infliximab treatment in ulcerative colitis are limited. AIM: To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined. METHODS: A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant...
December 27, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28008631/systematic-review-with-meta-analysis-the-management-of-chronic-refractory-pouchitis-with-an-evidence-based-treatment-algorithm
#14
REVIEW
J P Segal, N S Ding, G Worley, S Mclaughlin, S Preston, O D Faiz, S K Clark, A L Hart
BACKGROUND: Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy. The incidence of pouchitis is 40% at 5 years. Ten to 15% of patients with pouchitis experience chronic pouchitis. AIM: To determine the efficacy of medical therapies for the treatment of chronic refractory pouchitis in patients undergoing IPAA for UC. METHODS: A systematic computer-assisted search of the on-line bibliographic database MEDLINE and EMBASE was performed between 1966 and February 2016...
December 23, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28004405/expert-clinical-management-of-autoimmune-hepatitis-in-the-real-world
#15
R Liberal, Y S de Boer, R J Andrade, G Bouma, G N Dalekos, A Floreani, D Gleeson, G M Hirschfield, P Invernizzi, M Lenzi, A W Lohse, G Macedo, P Milkiewicz, B Terziroli, B van Hoek, J M Vierling, M A Heneghan
BACKGROUND: High-quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still expert based rather than evidence based. AIM: To survey expert hepatologists, asking each to describe their practices in the management of patients with AIH. METHODS: A survey questionnaire was distributed to members of the International AIH Group. The questionnaire consisted of four clinical scenarios on different presentations of AIH...
December 22, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27995656/the-effects-of-aminosalicylates-or-thiopurines-on-the-risk-of-colorectal-cancer-in-inflammatory-bowel-disease
#16
F Carrat, P Seksik, J-F Colombel, L Peyrin-Biroulet, L Beaugerie
BACKGROUND: Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer (CRC) in inflammatory bowel (IBD) disease is controversial. AIM: To assess simultaneously the chemopreventive effect of aminosalicylates or thiopurines in a case-control study nested in the CESAME observational cohort that enrolled consecutive patients with IBD between May 2004 and June 2005. Patients were followed up to December 2007. METHODS: Study population comprised 144 case patients who developed CRC from the diagnosis of IBD (65 and 79 cases diagnosed, respectively, before and from 2004, starting year of the prospective observational period of CESAME) and 286 controls matched for gender, age, IBD subtype and year of diagnosis, and cumulative extent of colitis...
December 19, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27976416/effects-of-nucleoside-analogue-prescription-for-hepatitis-b-on-the-incidence-of-liver-cancer-in-hong-kong-a-territory-wide-ecological-study
#17
W-K Seto, E H Y Lau, J T K Wu, I F N Hung, W K Leung, K-S Cheung, J Fung, C-L Lai, M-F Yuen
BACKGROUND: The temporal relationship between nucleoside analogue (NA) therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level. AIM: To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB-prevalent region. METHODS: We obtained territory-wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population-based liver cancer incidence data from 1990 to 2012...
December 15, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27957759/systematic-review-recurrent-autoimmune-liver-diseases-after-liver-transplantation
#18
REVIEW
A J Montano-Loza, R A Bhanji, S Wasilenko, A L Mason
BACKGROUND: Autoimmune liver diseases (AILD) constitute the third most common indication for liver transplantation (LT) worldwide. Outcomes post LT are generally good but recurrent disease is frequently observed. AIMS: To describe the frequency and risk factors associated with recurrent AILD post-LT and provide recommendations to reduce the incidence of recurrence based on levels of evidence. METHODS: A systematic review was performed for full-text papers published in English-language journals, using the keywords 'autoimmune hepatitis (AIH)', 'primary biliary cholangitis and/or cirrhosis (PBC)', 'primary sclerosing cholangitis (PSC)', 'liver transplantation' and 'recurrent disease'...
December 12, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27925255/the-course-of-achalasia-one-to-four-decades-after-initial-treatment
#19
T Sawas, K Ravi, D M Geno, F Enders, K Pierce, D Wigle, D A Katzka
BACKGROUND: Most follow-up studies of achalasia are limited to <5 years. AIMS: To study the long-term efficacy of pneumatic dilation (PD) and myotomy in achalasia at least 10 years after treatment. METHODS: We performed a retrospective cohort study of achalasia patients with >10 years follow-up after initial myotomy or pneumatic dilation. Symptom recurrence which required repeat dilation or surgery was compared between pneumatic dilation and myotomy...
December 7, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28074519/letter-levofloxacin-resistance-a-challenge-for-treatment-of-helicobacter-pylori-infection-authors-reply
#20
LETTER
P-Y Chen, M-S Wu, J-M Liou
No abstract text is available yet for this article.
February 2017: Alimentary Pharmacology & Therapeutics
journal
journal
29552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"